

Special Issue

New Advances in Metabolic Diseases Diagnostics and Treatment: From Basic Research to Clinical Practice

Message from the Guest Editor

Our goal is to spotlight novel advances in the field of genetic or non-genetic Metabolic Disorders, covering aspects that may range from basic research to clinical diagnosis and monitoring. We hope that reporting new hypotheses and observations may allow researchers to integrate the metabolic processes involving proteins (amino acids), carbohydrates (sugars), or lipids (fatty acids). The regulation of mitochondrial function and bioenergetics, metabolites transport across membranes, intracellular communication, post-translational modifications of proteins, and enzyme activity are crucial in biosynthesis versus degradation pathways. The roles of dietary components or specific small molecules in prevention and/or pathogenesis are also significant. Original research articles and reviews reporting innovations in biomarkers assessments using human samples, human tissues or digital technologies, cell-based assays or models of metabolic disease are encouraged. Comprehensive tools and technologies focusing on metabolomics, proteomics, lipidomics, and multi-omics or multi-modal approaches are of particular interest.

Guest Editor

Dr. Margarida F. B. Silva

Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

Deadline for manuscript submissions

31 May 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/177414

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).